Adhd – Exclusive Deal

DSM-5 requires onset before age 12, but longitudinal studies (e.g., the Dunedin cohort) identify a small group (~5-10% of adult ADHD cases) with first symptoms emerging in adulthood without childhood history. Whether this represents late-onset ADHD, a distinct disorder, or misattribution of symptoms to other conditions remains debated.

Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most prevalent neurodevelopmental disorders, affecting approximately 5-7% of children and 2.5% of adults worldwide. Once viewed as a childhood-limited condition characterized by hyperactivity and inattention, contemporary research frames ADHD as a lifelong, heterogeneous disorder of executive function, reward processing, and temporal processing. This paper synthesizes current findings on the genetic and neurobiological underpinnings—highlighting dopaminergic and noradrenergic dysregulation in fronto-striatal-cerebellar circuits. It critically evaluates diagnostic challenges, including sex-based phenotypic differences and high comorbidity with autism spectrum disorder (ASD), anxiety, and oppositional defiant disorder (ODD). Evidence-based interventions are reviewed: stimulant pharmacotherapy (methylphenidate, amphetamines), non-stimulants (atomoxetine, guanfacine), and behavioral therapies. Finally, the paper addresses the emerging adult ADHD phenotype, including risks for occupational instability, substance use, and accidental injury, while advocating for lifespan, multimodal management. DSM-5 requires onset before age 12, but longitudinal

*SMD = Standardized Mean Difference vs. placebo; values from Cortese et al. (2018) Lancet Psychiatry. and behavioral therapies. Finally